Sector Update: Healthcare
Healthcare shares are mixed in pre-market trade. Onyx Pharmaceuticals, Inc. ( ONXX ) and partner Bayer HealthCare said that the European Commission has approved Stivarga tablets for the treatment of adult patients with metastatic colorectal cancer. In September 2012, Stivarga was approved by the U.S. Food and Drug Administration.
The approval of Stivarga was based on data from the pivotal Phase III CORRECT trial. ONXX closed at $123.60 on Thursday, near 52-week high $136.87.
And, ThermoGenesis ( KOOL ) is up 3.3% at $1.24 in pre-market trade after it reported a Q4 loss of $0.14 per share on revenues of $4.1 million. This compares to a loss per share of $0.04 on revenues of $4.5 million in the same quarter a year ago.
No analyst estimates were available for comparison. Shares have a 52-week range of $0.61 - $1.60.